



Drug Shortage

Hydralazine 20 mg/mL x 1 mL vial

The issue: Hydralazine 20 mg/mL x 1 mL is single source from Sterimax who have indicated the drug is on backorder until late March 2019.

NH stock status: NH has approximately six weeks of inventory and we anticipate we will stock out mid to late January 2019.

Practice Implications:

- Clinicians should be aware of this shortage.
- Use therapeutic alternatives where possible to conserve existing hydralazine stock for high priority indications and locations.
- High priority indications include the acute management of severe hypertension in pregnancy that is non-responsive to IV labetalol. High priority patient care areas include the Emergency Department and Obstetrics/Maternity.
- Step down to oral anti-hypertensive therapy as soon as clinically appropriate.

Alternatives*: Use parenteral therapy options where appropriate and refer to the NH Parenteral Drug Administration Manual for information on intravenous drug administration.

- Labetalol injection
- Esmolol injection
- Enalaprilat injection
- Nitroglycerin injection
- Nitroprusside injection (also on reduced availability)

| | | | |
|--|----------------------|---|---|
| <p>December 13, 2018</p> <p>For the information of physicians, nurses and pharmacists</p> <p>PLEASE POST</p> | Drug Shortage | ✓ | <p>For further information contact: NH Medication Use Management Pharmacists: Gordon Harper (778-349-3216) Jessica Brecknock (250-267-5940) mumpharmacist@northernhealth.ca</p> |
| | Formulary change | | |
| | Best Practice | | |
| | Recall | | |
| | Label Change | | |